Alcon Inc. (SWX:ALC)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 31.21B |
| Revenue (ttm) | 8.12B |
| Net Income (ttm) | 834.86M |
| Shares Out | 491.20M |
| EPS (ttm) | 1.67 |
| PE Ratio | 37.95 |
| Forward PE | 24.37 |
| Dividend | 0.28 (0.44%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 843,146 |
| Average Volume | 1,027,049 |
| Open | 64.16 |
| Previous Close | 63.54 |
| Day's Range | 63.62 - 65.50 |
| 52-Week Range | 57.68 - 87.00 |
| Beta | 0.69 |
| RSI | 62.99 |
| Earnings Date | Feb 26, 2026 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
STAAR Surgical (STAA) Faces Potential Delay in Alcon (ALC) Acquisition Vote
STAAR Surgical (STAA) Faces Potential Delay in Alcon (ALC) Acquisition Vote
STAAR Surgical vote on Alcon may be delayed again - report
Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the confe...
Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live web...
Alcon (ALC) Faces Opposition in STAAR Surgical Acquisition
Alcon (ALC) Faces Opposition in STAAR Surgical Acquisition
Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
STAAR Surgical (STAA) Rises Amid Adjourned Shareholder Vote on Alcon Deal
STAAR Surgical (STAA) Rises Amid Adjourned Shareholder Vote on Alcon Deal
Alcon (ALC) Postpones Special Meeting to January 2026
Alcon (ALC) Postpones Special Meeting to January 2026
STAAR Surgical gains as special meeting on Alcon deal is adjourned
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right...
Lensar: Timing And Arbitrage Considerations In Alcon's Acquisition Bid
Get the latest on Alcon's pending acquisition of LENSAR—deal updates, regulatory hurdles, and investment outlook.
Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C. , Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareh...
Alcon (ALC) Acquisition of STAAR Surgical Faces Strong Opposition
Alcon (ALC) Acquisition of STAAR Surgical Faces Strong Opposition
Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
Alcon (ALC) Merger Proposal Faces Crucial Vote by STAAR Shareholders
Alcon (ALC) Merger Proposal Faces Crucial Vote by STAAR Shareholders
STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Yunqi Capital Opposes Alcon's Acquisition Proposal for STAAR Surgical (ALC)
Yunqi Capital Opposes Alcon's Acquisition Proposal for STAAR Surgical (ALC)
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Alcon (ALC) Replaced on Needham's Conviction List
Alcon (ALC) Replaced on Needham's Conviction List
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on a report published by Institutional Shareholder Services Inc. (“ISS”), an independent pr...
STAAR Surgical (STAA) Gains as ISS Backs Alcon's Improved Offer
STAAR Surgical (STAA) Gains as ISS Backs Alcon's Improved Offer
STAAR Surgical gains as proxy adviser ISS supports revised Alcon deal
STAAR Surgical shares jump after ISS backs Alcon's $30.75 buyout offer. Discover key shareholder moves and what this means ahead of the Dec. 19 vote.
Staar Surgical Endorses Alcon (ALC) Merger, Backed by New ISS Report
Staar Surgical Endorses Alcon (ALC) Merger, Backed by New ISS Report
STAAR Surgical (STAA) Faces Investor Pushback on Alcon Offer
STAAR Surgical (STAA) Faces Investor Pushback on Alcon Offer